Emerging anticoagulant strategies

Despite the introduction of direct oral anticoagulants (DOACs), the search for more effective and safer antithrombotic strategies continues. Better understanding of the pathogenesis of thrombosis has fostered 2 new approaches to achieving this goal. First, evidence that thrombin may be as important...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2017-01, Vol.129 (2), p.147-154
Hauptverfasser: Fredenburgh, James C., Gross, Peter L., Weitz, Jeffrey I.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 154
container_issue 2
container_start_page 147
container_title Blood
container_volume 129
creator Fredenburgh, James C.
Gross, Peter L.
Weitz, Jeffrey I.
description Despite the introduction of direct oral anticoagulants (DOACs), the search for more effective and safer antithrombotic strategies continues. Better understanding of the pathogenesis of thrombosis has fostered 2 new approaches to achieving this goal. First, evidence that thrombin may be as important as platelets to thrombosis at sites of arterial injury and that platelets contribute to venous thrombosis has prompted trials comparing anticoagulants with aspirin for secondary prevention in arterial thrombosis and aspirin with anticoagulants for primary and secondary prevention of venous thrombosis. These studies will help identify novel treatment strategies. Second, emerging data that naturally occurring polyphosphates activate the contact system and that this system is critical for thrombus stabilization and growth have identified factor XII (FXII) and FXI as targets for new anticoagulants that may be even safer than the DOACs. Studies are needed to determine whether FXI or FXII is the better target and to compare the efficacy and safety of these new strategies with current standards of care for the prevention or treatment of thrombosis. Focusing on these advances, this article outlines how treatment strategies for thrombosis are evolving and describes the rationale and approaches to targeting FXII and FXI. These emerging anticoagulant strategies should address unmet needs and reduce the systemic underuse of anticoagulation because of the fear of bleeding.
doi_str_mv 10.1182/blood-2016-09-692996
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1835687520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120337964</els_id><sourcerecordid>1835687520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-62a5968700ef90ea12f0e7e8832320a63367934cdfce1a6d2d69a3576e813a9d3</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EoqXwDxAqG4vhbCeOvSChqnxIlVhgtlz7EhklTbETJP59U1IYme6G9-PuIeSSwS1jit-t67b1lAOTFDSVmmstj8iU5VxRAA7HZAoAkma6YBNyltIHAMsEz0_JhBeFAgViSq6XDcYqbKq53XTBtbbq62Gbpy7aDquA6ZyclLZOeHGYM_L-uHxbPNPV69PL4mFFXQaqo5LbXEtVAGCpAS3jJWCBSgkuOFgphCy0yJwvHTIrPfdSW5EXEhUTVnsxIzdj7ja2nz2mzjQhOayHc7Dtk2FK5EN-zmGQZqPUxTaliKXZxtDY-G0YmD0c8wPH7OEY0GaEM9iuDg39ukH_Z_qlMQjuRwEOf34FjCa5gBuHPkR0nfFt-L9hBxlUdD4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835687520</pqid></control><display><type>article</type><title>Emerging anticoagulant strategies</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Fredenburgh, James C. ; Gross, Peter L. ; Weitz, Jeffrey I.</creator><creatorcontrib>Fredenburgh, James C. ; Gross, Peter L. ; Weitz, Jeffrey I.</creatorcontrib><description>Despite the introduction of direct oral anticoagulants (DOACs), the search for more effective and safer antithrombotic strategies continues. Better understanding of the pathogenesis of thrombosis has fostered 2 new approaches to achieving this goal. First, evidence that thrombin may be as important as platelets to thrombosis at sites of arterial injury and that platelets contribute to venous thrombosis has prompted trials comparing anticoagulants with aspirin for secondary prevention in arterial thrombosis and aspirin with anticoagulants for primary and secondary prevention of venous thrombosis. These studies will help identify novel treatment strategies. Second, emerging data that naturally occurring polyphosphates activate the contact system and that this system is critical for thrombus stabilization and growth have identified factor XII (FXII) and FXI as targets for new anticoagulants that may be even safer than the DOACs. Studies are needed to determine whether FXI or FXII is the better target and to compare the efficacy and safety of these new strategies with current standards of care for the prevention or treatment of thrombosis. Focusing on these advances, this article outlines how treatment strategies for thrombosis are evolving and describes the rationale and approaches to targeting FXII and FXI. These emerging anticoagulant strategies should address unmet needs and reduce the systemic underuse of anticoagulation because of the fear of bleeding.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2016-09-692996</identifier><identifier>PMID: 27780803</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Anticoagulants - pharmacology ; Blood Coagulation - drug effects ; Blood Coagulation - physiology ; Factor XI - antagonists &amp; inhibitors ; Factor XII - antagonists &amp; inhibitors ; Humans ; Thrombosis - metabolism</subject><ispartof>Blood, 2017-01, Vol.129 (2), p.147-154</ispartof><rights>2017 American Society of Hematology</rights><rights>2017 by The American Society of Hematology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-62a5968700ef90ea12f0e7e8832320a63367934cdfce1a6d2d69a3576e813a9d3</citedby><cites>FETCH-LOGICAL-c408t-62a5968700ef90ea12f0e7e8832320a63367934cdfce1a6d2d69a3576e813a9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27780803$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fredenburgh, James C.</creatorcontrib><creatorcontrib>Gross, Peter L.</creatorcontrib><creatorcontrib>Weitz, Jeffrey I.</creatorcontrib><title>Emerging anticoagulant strategies</title><title>Blood</title><addtitle>Blood</addtitle><description>Despite the introduction of direct oral anticoagulants (DOACs), the search for more effective and safer antithrombotic strategies continues. Better understanding of the pathogenesis of thrombosis has fostered 2 new approaches to achieving this goal. First, evidence that thrombin may be as important as platelets to thrombosis at sites of arterial injury and that platelets contribute to venous thrombosis has prompted trials comparing anticoagulants with aspirin for secondary prevention in arterial thrombosis and aspirin with anticoagulants for primary and secondary prevention of venous thrombosis. These studies will help identify novel treatment strategies. Second, emerging data that naturally occurring polyphosphates activate the contact system and that this system is critical for thrombus stabilization and growth have identified factor XII (FXII) and FXI as targets for new anticoagulants that may be even safer than the DOACs. Studies are needed to determine whether FXI or FXII is the better target and to compare the efficacy and safety of these new strategies with current standards of care for the prevention or treatment of thrombosis. Focusing on these advances, this article outlines how treatment strategies for thrombosis are evolving and describes the rationale and approaches to targeting FXII and FXI. These emerging anticoagulant strategies should address unmet needs and reduce the systemic underuse of anticoagulation because of the fear of bleeding.</description><subject>Animals</subject><subject>Anticoagulants - pharmacology</subject><subject>Blood Coagulation - drug effects</subject><subject>Blood Coagulation - physiology</subject><subject>Factor XI - antagonists &amp; inhibitors</subject><subject>Factor XII - antagonists &amp; inhibitors</subject><subject>Humans</subject><subject>Thrombosis - metabolism</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAQhi0EoqXwDxAqG4vhbCeOvSChqnxIlVhgtlz7EhklTbETJP59U1IYme6G9-PuIeSSwS1jit-t67b1lAOTFDSVmmstj8iU5VxRAA7HZAoAkma6YBNyltIHAMsEz0_JhBeFAgViSq6XDcYqbKq53XTBtbbq62Gbpy7aDquA6ZyclLZOeHGYM_L-uHxbPNPV69PL4mFFXQaqo5LbXEtVAGCpAS3jJWCBSgkuOFgphCy0yJwvHTIrPfdSW5EXEhUTVnsxIzdj7ja2nz2mzjQhOayHc7Dtk2FK5EN-zmGQZqPUxTaliKXZxtDY-G0YmD0c8wPH7OEY0GaEM9iuDg39ukH_Z_qlMQjuRwEOf34FjCa5gBuHPkR0nfFt-L9hBxlUdD4</recordid><startdate>20170112</startdate><enddate>20170112</enddate><creator>Fredenburgh, James C.</creator><creator>Gross, Peter L.</creator><creator>Weitz, Jeffrey I.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170112</creationdate><title>Emerging anticoagulant strategies</title><author>Fredenburgh, James C. ; Gross, Peter L. ; Weitz, Jeffrey I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-62a5968700ef90ea12f0e7e8832320a63367934cdfce1a6d2d69a3576e813a9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Anticoagulants - pharmacology</topic><topic>Blood Coagulation - drug effects</topic><topic>Blood Coagulation - physiology</topic><topic>Factor XI - antagonists &amp; inhibitors</topic><topic>Factor XII - antagonists &amp; inhibitors</topic><topic>Humans</topic><topic>Thrombosis - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fredenburgh, James C.</creatorcontrib><creatorcontrib>Gross, Peter L.</creatorcontrib><creatorcontrib>Weitz, Jeffrey I.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fredenburgh, James C.</au><au>Gross, Peter L.</au><au>Weitz, Jeffrey I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Emerging anticoagulant strategies</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2017-01-12</date><risdate>2017</risdate><volume>129</volume><issue>2</issue><spage>147</spage><epage>154</epage><pages>147-154</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Despite the introduction of direct oral anticoagulants (DOACs), the search for more effective and safer antithrombotic strategies continues. Better understanding of the pathogenesis of thrombosis has fostered 2 new approaches to achieving this goal. First, evidence that thrombin may be as important as platelets to thrombosis at sites of arterial injury and that platelets contribute to venous thrombosis has prompted trials comparing anticoagulants with aspirin for secondary prevention in arterial thrombosis and aspirin with anticoagulants for primary and secondary prevention of venous thrombosis. These studies will help identify novel treatment strategies. Second, emerging data that naturally occurring polyphosphates activate the contact system and that this system is critical for thrombus stabilization and growth have identified factor XII (FXII) and FXI as targets for new anticoagulants that may be even safer than the DOACs. Studies are needed to determine whether FXI or FXII is the better target and to compare the efficacy and safety of these new strategies with current standards of care for the prevention or treatment of thrombosis. Focusing on these advances, this article outlines how treatment strategies for thrombosis are evolving and describes the rationale and approaches to targeting FXII and FXI. These emerging anticoagulant strategies should address unmet needs and reduce the systemic underuse of anticoagulation because of the fear of bleeding.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27780803</pmid><doi>10.1182/blood-2016-09-692996</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2017-01, Vol.129 (2), p.147-154
issn 0006-4971
1528-0020
language eng
recordid cdi_proquest_miscellaneous_1835687520
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Animals
Anticoagulants - pharmacology
Blood Coagulation - drug effects
Blood Coagulation - physiology
Factor XI - antagonists & inhibitors
Factor XII - antagonists & inhibitors
Humans
Thrombosis - metabolism
title Emerging anticoagulant strategies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A35%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Emerging%20anticoagulant%20strategies&rft.jtitle=Blood&rft.au=Fredenburgh,%20James%20C.&rft.date=2017-01-12&rft.volume=129&rft.issue=2&rft.spage=147&rft.epage=154&rft.pages=147-154&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2016-09-692996&rft_dat=%3Cproquest_cross%3E1835687520%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835687520&rft_id=info:pmid/27780803&rft_els_id=S0006497120337964&rfr_iscdi=true